191 related articles for article (PubMed ID: 15088322)
1. Low-dose aspirin in polycythemia vera.
Dutrillaux F; Maynadié M; Carli PM
N Engl J Med; 2004 Apr; 350(16):1683-5; author reply 1683-5. PubMed ID: 15088322
[No Abstract] [Full Text] [Related]
2. Low-dose aspirin in polycythemia vera.
Denes AE
N Engl J Med; 2004 Apr; 350(16):1683-5; author reply 1683-5. PubMed ID: 15088323
[No Abstract] [Full Text] [Related]
3. Aspirin for the control of platelet activation and prevention of thrombosis in essential thrombocythemia and polycythemia vera: current insights and rationale for future studies.
Landolfi R; Di Gennaro L; Novarese L; Patrono C
Semin Thromb Hemost; 2006 Apr; 32(3):251-9. PubMed ID: 16673279
[TBL] [Abstract][Full Text] [Related]
4. [Essential thrombocythemia: antiaggregants].
Cortelazzo S; Barbui T
Haematologica; 1991 Jun; 76 Suppl 3():371-3. PubMed ID: 1752535
[No Abstract] [Full Text] [Related]
5. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia.
Michiels JJ; Berneman Z; Schroyens W; Koudstaal PJ; Lindemans J; Neumann HA; van Vliet HH
Platelets; 2006 Dec; 17(8):528-44. PubMed ID: 17127481
[TBL] [Abstract][Full Text] [Related]
6. Pericardial hemorrhage due to acetylsalicylic acid in a patient with essential thrombocythemia.
Kayrak M; Acar K; Yazici M; Kaya C; Ayhan SS; Gok H
Clin Appl Thromb Hemost; 2009; 15(4):465-6. PubMed ID: 18160579
[TBL] [Abstract][Full Text] [Related]
7. Low-dose aspirin in polycythemia vera.
Alliot C
N Engl J Med; 2004 Apr; 350(16):1683-5; author reply 1683-5. PubMed ID: 15084704
[No Abstract] [Full Text] [Related]
8. Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia.
Squizzato A; Romualdi E; Middeldorp S
Cochrane Database Syst Rev; 2008 Apr; (2):CD006503. PubMed ID: 18425953
[TBL] [Abstract][Full Text] [Related]
9. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
[TBL] [Abstract][Full Text] [Related]
10. Aspirin in polycythemia vera and essential thrombocythemia: current facts and perspectives.
Landolfi R; Patrono C
Leuk Lymphoma; 1996 Sep; 22 Suppl 1():83-6. PubMed ID: 8951777
[TBL] [Abstract][Full Text] [Related]
11. Risk-adapted therapy in essential thrombocythemia and polycythemia vera.
Finazzi G; Barbui T
Blood Rev; 2005 Sep; 19(5):243-52. PubMed ID: 15963833
[TBL] [Abstract][Full Text] [Related]
12. Pathogenesis and management of bleeding in essential thrombocythemia and polycythemia vera.
Elliott MA; Tefferi A
Curr Hematol Rep; 2004 Sep; 3(5):344-51. PubMed ID: 15341701
[TBL] [Abstract][Full Text] [Related]
13. [Prevention of vascular complications in polycythemia vera and primary thrombocythemia treated with low doses of acetylsalicylic acid].
Fröhli P; Graf C; Rhyner K
Schweiz Med Wochenschr; 1983 Nov; 113(44):1622-7. PubMed ID: 6685916
[TBL] [Abstract][Full Text] [Related]
14. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Marchioli R; Leone G; Barbui T;
Haematologica; 2008 Mar; 93(3):372-80. PubMed ID: 18268279
[TBL] [Abstract][Full Text] [Related]
15. Prevention of thrombosis in polycythemia vera and essential thrombocythemia.
Landolfi R; Di Gennaro L
Haematologica; 2008 Mar; 93(3):331-5. PubMed ID: 18310537
[No Abstract] [Full Text] [Related]
16. [Therapeutic effect of ranimustine (MCNU) on essential thrombocythemia and polycythemia vera].
Nagai M; Tasaka T; Kamano H; Ohnishi H; Taoka T; Ikeda K; Kubota Y; Tanaka T; Irino S
Gan To Kagaku Ryoho; 1988 Dec; 15(12):3267-70. PubMed ID: 3196045
[TBL] [Abstract][Full Text] [Related]
17. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
Michiels JJ; Berneman Z; Schroyens W; Finazzi G; Budde U; van Vliet HH
Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569
[TBL] [Abstract][Full Text] [Related]
18. Anagrelide-associated cardiomyopathy in polycythemia vera and essential thrombocythemia.
Jurgens DJ; Moreno-Aspitia A; Tefferi A
Haematologica; 2004 Nov; 89(11):1394-5. PubMed ID: 15531464
[TBL] [Abstract][Full Text] [Related]
19. Management of Philadelphia negative chronic myeloproliferative disorders in pregnancy.
Griesshammer M; Struve S; Barbui T
Blood Rev; 2008 Sep; 22(5):235-45. PubMed ID: 18617299
[TBL] [Abstract][Full Text] [Related]
20. Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk.
Barbui T; Finazzi G
Semin Thromb Hemost; 2007 Jun; 33(4):321-9. PubMed ID: 17525889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
